Core Viewpoint - Altimmune, Inc. announces a CEO succession plan with Jerry Durso set to replace Vipin Garg, Ph.D. as President and CEO effective January 1, 2026, following Garg's seven-year leadership [2][4]. Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and metabolic diseases, with its lead product candidate being pemvidutide, a dual glucagon and GLP-1 receptor agonist [8][9]. Leadership Transition - Vipin Garg will step down as CEO but will remain as an advisor until June 30, 2026, to ensure a smooth transition [2][3]. - Jerry Durso, the current Chairman of the Board, will take over as CEO while retaining his chairman position [2][5]. Achievements Under Current Leadership - Under Dr. Garg's leadership, Altimmune advanced its lead candidate pemvidutide from a preclinical stage to a Phase 3 ready program for metabolic dysfunction-associated steatohepatitis (MASH) [3][4]. - The company has ongoing Phase 2 clinical programs for alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) [3]. Future Prospects - Pemvidutide has shown significant potential in reducing liver inflammation and fibrosis, as well as achieving notable weight loss with good tolerability in patients with MASH [4]. - Altimmune is preparing for an End-of-Phase 2 meeting with the FDA to discuss trial design and study endpoints for the Phase 3 MASH program, with 48-week data from the IMPACT Phase 2b trial expected before year-end [4][6]. Jerry Durso's Background - Jerry Durso brings over 30 years of leadership experience in the life sciences industry, including a successful tenure as CEO of Intercept Pharmaceuticals, where he focused on liver diseases [7]. - His experience includes overseeing multiple blockbuster franchises at Sanofi, enhancing corporate strategy, and leading successful acquisitions [7].

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows: Conference: Piper Sandler 37th Annual Healthcare ConferenceDate/Time: Wednesday, December 3, 2025 at 2:30 p.m. ET The ...

Shares of Altimmune, Inc. (ALT) have gained 23.2% over the past four weeks to close the last trading session at $5.1, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.88 indicates a potential upside of 250.6%.The mean estimate comprises eight short-term price targets with a standard deviation of $8.81. While the lowest estimate of $1.00 indicates a 80.4% decline from the curr ...

Core Insights - The company is developing a glucagon GLP-1 dual receptor agonist aimed at treating liver diseases such as MASH, AUD, and ALD, which combines the effects of GLP-1 and glucagon in a 1:1 ratio [1] - The dual mechanism is designed to provide both direct effects in the liver and metabolic benefits, including appetite suppression and weight loss [1] - The drug features a unique pharmacokinetic (PK) profile due to the proprietary EuPort domain, which slows the entry of the drug into the bloodstream, resulting in a longer duration of action [2]

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune (NasdaqGM:ALT) - **Focus**: Development of a glucagon GLP-1 dual receptor agonist, pemvidutide, targeting liver diseases such as MASH (Metabolic Associated Steatotic Liver Disease), AUD (Alcohol Use Disorder), and ALD (Alcoholic Liver Disease) [4][39] Core Points and Arguments Product Development - **Pemvidutide**: A rationally designed molecule with a one-to-one ratio of GLP-1 and glucagon, aimed at providing both direct liver effects and metabolic benefits such as weight loss [4][36] - **Unique PK Profile**: The proprietary UPORT domain slows drug entry into the bloodstream, resulting in longer Tmax and lower Cmax, contributing to a favorable tolerability profile [5][28] - **Clinical Trials**: - Completed enrollment in a 48-week trial for MASH, with 24-week data already presented [5][6] - Anticipating 48-week data release in Q4 2025 and an FDA end-of-phase two meeting [5][6] Clinical Data - **24-Week Results**: Showed a 60% response rate in MASH resolution, comparable to other programs at longer durations [8][36] - **Non-Invasive Tests**: Focus on non-invasive tests for assessing liver fat and fibrosis, with expectations for continued improvement in these markers [10][15] - **Weight Loss**: Significant weight loss observed without plateauing, with a focus on preserving lean mass, crucial for older patients [20][21][22] Regulatory Strategy - **FDA Engagement**: Seeking alignment with the FDA on phase three program design, particularly regarding non-invasive testing (NITs) and potential for accelerated approval [24][26] - **Flexibility in Design**: Prepared to adapt trial designs based on evolving regulatory requirements, including the potential shift from biopsy to NIT endpoints [26][30] Market Positioning - **Differentiation**: Pemvidutide is positioned as a first-line therapy for MASH due to its dual mechanism of action, targeting both liver health and metabolic aspects [31][35] - **Competitive Landscape**: Distinction from other GLP-1 therapies, emphasizing direct liver impact and rapid fibrosis improvement [32][36] - **Pricing Strategy**: Focus on broad-spectrum benefits, including weight loss and liver health improvement, to appeal to patients, physicians, and payers [36][38] Additional Insights - **ALD and AUD Programs**: Enrollment completed for AUD study, with ongoing ALD study, highlighting the potential for a comprehensive liver health portfolio [39][40] - **Patient Demographics**: Targeting older populations with MASH, AUD, and ALD, emphasizing the importance of tolerability and quality of life improvements [21][41] Conclusion Altimmune is advancing its pemvidutide program with promising clinical data and a strategic approach to regulatory engagement, positioning itself favorably in the liver disease treatment landscape. The dual mechanism of action and focus on tolerability are key differentiators that may enhance its market potential.

Core Insights - The article discusses the recent performance and outlook of Altimmue (ALT), particularly following the Phase IIb MASH data readout that negatively impacted the share price, suggesting that the selloff was more of a panic reaction rather than a reflection of the company's fundamentals [1]. Group 1: Company Overview - Altimmue (ALT) has experienced significant volatility in its stock price, particularly after the release of Phase IIb MASH data [1]. - The author believes that the market's reaction to the data was exaggerated, indicating potential for recovery and investment opportunity [1]. Group 2: Investment Strategy - The author emphasizes a focus on innovative companies in the biotech sector that are developing breakthrough therapies, which may present catalysts for potential acquisitions [1]. - The investment group, Compounding Healthcare, offers various resources including model healthcare portfolios, newsletters, and a daily watchlist to assist investors [1].

Core Insights - The article discusses the recent performance and outlook of Altimmue (ALT), particularly following the Phase IIb MASH data readout that negatively impacted the share price, suggesting that the selloff was more of a panic reaction rather than a justified market response [1]. Group 1: Company Overview - Altimmue (ALT) has experienced significant volatility in its share price due to recent clinical data releases, specifically the Phase IIb MASH data [1]. - The author believes that the market's reaction to the Phase IIb data was exaggerated, indicating potential for recovery and investment opportunity [1]. Group 2: Investment Strategy - The focus of the analysis is on identifying innovative companies in the biotech sector that are developing breakthrough therapies, which may present catalysts for potential acquisitions [1]. - The author leads an investment group, Compounding Healthcare, which provides resources such as model healthcare portfolios, newsletters, and daily watchlists to assist investors in making informed decisions [1].

Summary of Altimmune Conference Call Company Overview - **Company**: Altimmune - **Key Product**: Pemvidutide (Pemvi), a GLP-1 glucagon dual receptor agonist for treating serious liver diseases such as MASH (Metabolic Associated Steatotic Liver Disease), AUD (Alcohol Use Disorder), and ALD (Alcoholic Liver Disease) [1][2][3] Core Points and Arguments Product Development and Mechanism - Pemvidutide is designed to provide a balanced agonist effect on both glucagon and GLP-1 receptors, targeting liver health and metabolic benefits simultaneously [2][3] - The drug aims to treat MASH effectively by combining anti-inflammatory and anti-fibrotic effects with metabolic improvements [3][4] - Recent 24-week data showed significant improvements in MASH resolution, anti-fibrotic activity, and weight loss, preserving lean mass, which is crucial for the patient population [4][12] Competitive Landscape - The MASH treatment landscape is becoming competitive with large pharmaceutical companies acquiring advanced FGF21 assets and exploring combination therapies [5][6] - Altimmune believes its dual mechanism of action positions Pemvidutide favorably against competitors, as it combines both liver-targeting and metabolic benefits in one molecule [6][13] Clinical Data and Expectations - The 48-week study readout is anticipated in Q4, following a successful 24-week readout that demonstrated rapid MASH resolution and fibrosis improvement [2][16] - The company reported a 36% improvement in fibrosis without worsening MASH, although statistical significance was not achieved due to high placebo effects [17] - Non-invasive tests showed promising results, with a notable decrease in ELF scores, indicating effective treatment [17][19] Regulatory and Market Strategy - Altimmune is preparing for Phase III trials, with flexibility in endpoints to adapt to potential regulatory changes regarding biopsy requirements [32][34] - The FDA is engaged and supportive of advancing Pemvidutide, with a meeting scheduled to discuss the drug's development [18][33] Financial Position - Altimmune reported a strong financial position with approximately $211 million in cash at the end of the quarter, enabling continued development through 2026 and 2027 [50] Additional Important Insights - The tolerability of Pemvidutide is highlighted as a key differentiator, with a lower discontinuation rate compared to other glucagon GLP-1 receptor agonists [10][36] - The drug's ability to preserve lean mass during weight loss is particularly relevant for the aging population affected by MASH [12][44] - Altimmune is also exploring the use of Pemvidutide in AUD and ALD, leveraging its dual mechanism to address cravings and liver health simultaneously [41][42] Conclusion Altimmune is positioned strongly in the competitive landscape of liver disease treatments with Pemvidutide, showcasing promising clinical data and a robust financial foundation to support its ongoing development and regulatory strategy. The focus on dual mechanisms and tolerability may provide a significant advantage in treating MASH, AUD, and ALD.

Core Insights - Altimmune, Inc. announced significant 24-week efficacy and safety data from the IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH), showing promising results in MASH resolution, weight loss, and anti-fibrotic activity [1][3][5] Group 1: Trial Results - The IMPACT Phase 2b trial demonstrated that pemvidutide achieved statistically significant MASH resolution without worsening fibrosis, with 58% and 52% of patients in the 1.2 mg and 1.8 mg groups respectively achieving this outcome compared to 20% in the placebo group [6] - Significant improvements were observed in secondary endpoints, including a reduction in liver stiffness measurement and Enhanced Liver Fibrosis score, with the 1.2 mg and 1.8 mg groups showing reductions of -3.7 kPa and -2.2 kPa respectively [6] - The trial also reported a normalization of liver fat content in 31% and 44% of patients in the 1.2 mg and 1.8 mg groups respectively, compared to only 4% in the placebo group [6] Group 2: Safety and Tolerability - Pemvidutide exhibited a favorable tolerability profile, with only 2% of placebo patients experiencing adverse events leading to treatment discontinuation, compared to 0% in the 1.2 mg group and 1% in the 1.8 mg group [6] - Serious adverse events were reported in 3% of placebo patients, 2% in the 1.2 mg group, and 4% in the 1.8 mg group, with no serious adverse events deemed related to the treatment [6] Group 3: Future Outlook - The final readout of longer-term non-invasive tests and weight loss from the IMPACT trial is anticipated in the fourth quarter of 2025, which will provide further insights into the efficacy of pemvidutide [7][10] - The FDA has granted Fast Track designations to pemvidutide for the treatment of MASH and alcohol use disorder (AUD), indicating significant unmet medical needs in these areas [10]

Group 1 - Citizens JMP analyst Jonathan Wolleben lowered the price target on Altimmune (ALT) to $14 from $15 while maintaining an Outperform rating on the shares [1] - The firm anticipates the oral late-breaking presentation of pemvidutide's Phase 2b data at the Liver Meeting, with 48-week data expected to be released this quarter [1]